Literature DB >> 34413949

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34413949      PMCID： PMC8365997          DOI： 10.1021/acsmedchemlett.1c00393

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Opportunities for Small Molecules in Cancer Immunotherapy.

Authors:  Sabina Y van der Zanden; Jolien J Luimstra; Jacques Neefjes; Jannie Borst; Huib Ovaa
Journal:  Trends Immunol       Date:  2020-05-04       Impact factor: 16.687

Review 2.  Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy.

Authors:  Sundee Dees; Rajkumar Ganesan; Sanjaya Singh; Iqbal S Grewal
Journal:  Eur J Immunol       Date:  2020-12-28       Impact factor: 5.532

Review 3.  Targeting adenosine and regulatory T cells in cancer immunotherapy.

Authors:  Alexey Churov; Galina Zhulai
Journal:  Hum Immunol       Date:  2021-02-18       Impact factor: 2.850

Review 4.  Adenosine and adenosine receptors in colorectal cancer.

Authors:  Farnaz Hajizadeh; Ali Masjedi; Sima Heydarzedeh Asl; Fariba Karoon Kiani; Makwan Peydaveisi; Ghasem Ghalamfarsa; Farhad Jadidi-Niaragh; Andrey Sevbitov
Journal:  Int Immunopharmacol       Date:  2020-08-02       Impact factor: 4.932

Review 5.  Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle.

Authors:  Max M Wattenberg; Gregory L Beatty
Journal:  Semin Cancer Biol       Date:  2020-01-15       Impact factor: 15.707

Review 6.  Adenosine: The common target between cancer immunotherapy and glaucoma in the eye.

Authors:  Shahin Hallaj; Mohammad Mirza-Aghazadeh-Attari; Amin Arasteh; Anahita Ghorbani; Daniel Lee; Farhad Jadidi-Niaragh
Journal:  Life Sci       Date:  2021-07-08       Impact factor: 5.037
  6 in total
  1 in total

1.  Design, synthesis, and biological evaluation of triazole-pyrimidine-methylbenzonitrile derivatives as dual A2A/A2B adenosine receptor antagonists.

Authors:  Zhi Li; Lijuan Kou; Xinzhen Fu; Zeping Xie; Maolei Xu; Lin Guo; Tiantian Lin; Shizhou Gong; Shumin Zhang; Ming Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.